22 results
Thumbnail

D2.441 - Association of High Sensitive-C-reactive Protein with Left Ventricle Remodeling in Type 1 Diabetes Mellitus

Thumbnail

D2.443 - Serum Zonulin Reflects Disease Activity and Psychiatric Burden in Hereditary Angioedema

Thumbnail

D3.370 - Three cases of erdosteine-induced delayed drug hypersensitivity

Thumbnail

D3.373 - Non-immediate Hypersensitivity Reactions To Both Penicillin and Aminopenicillin and Diagnostic approach – A Real Life Retrospective Study

Thumbnail

D3.372 - Rapid Intramuscular Penicillin Desensitization: A Promising Future

Thumbnail

D3.374 - Recall urticaria to dalteparin sodium in a patient with previous systemic reaction to nadroparin calcium

Thumbnail

D3.375 - Delayed-Type Drug Reactions in Pediatric Patients: Clinical Features and Management

Thumbnail

D3.376 - Drug Allergy Related to Chemotherapy and Premedication: Anaphylaxis Induced by Carboplatin and Methylprednisolone

Thumbnail

D3.378 - Drug hypersensitivity in children in a frontline setting: interim results of a pilot epidemiological project

Thumbnail

D3.380 - The Most Serious Threat in Perioperative Hypersensitivity Reactions (PHRs): Neuromuscular Blocking Agent (NMBA) Hypersensitivity and Cisatracurium as a Safe Haven in the Setting of Cross-Reactivity

Thumbnail

D3.381 - The paradox of treatment: H1-antihistamines-induced urticaria in a patient with chronic spontaneous urticaria

Thumbnail

D3.382 - Safety and outcomes of penicillin desensitization during pregnancy: experience from a tertiary referral center

Thumbnail

D3.383 - Delayed T-cell–mediated hypersensitivity to dimethyl fumarate: clinical presentation and diagnostic considerations

Thumbnail

D3.384 - Assessment of the role of Rapid Drug Desensitization to treat cancer patient with infusion-related allergic reactions. Italian experience

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child